Investing

Viking Therapeutics : VKTX

VKTX

Stock Data

$34.22

$0.92 (2.76%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Viking Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing innovative treatments for metabolic and endocrine disorders. Its leading drug, VK2809, targets non-alcoholic steatohepatitis and NAFLD with a novel approach, aiming for efficacy and safety. Viking is also advancing VK5211 for hip fracture recovery, VK0612 for type 2 diabetes, VK2735 for metabolic diseases, and VK0214 for X-linked adrenoleukodystrophy, showcasing a diverse pipeline aimed at addressing significant unmet medical needs.

All Viking Therapeutics Articles

38 Articles

Joel South | Jul 29, 2026 at 8:00 AM EDT

3 Biotech Stocks With Massive Upside to Buy Before August Starts

FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk…

Joel South | Jul 9, 2026 at 8:00 AM EDT

3 High Growth GLP-1 Biotech Winners to Buy in July

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding…

Trey Thoelcke | Jun 23, 2026 at 7:55 AM EDT

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV…

Trey Thoelcke | May 26, 2026 at 8:50 AM EDT

If Viking Therapeutics Is Acquired, Here’s Who Wins

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX…

Alex Sirois | May 18, 2026 at 1:55 PM EDT

Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious:…

Trey Thoelcke | May 14, 2026 at 9:20 AM EDT

Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for…

Trey Thoelcke | Apr 10, 2026 at 8:25 AM EDT

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs.…

Trey Thoelcke | Apr 1, 2026 at 7:35 AM EDT

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual…

Trey Thoelcke | Feb 16, 2026 at 9:40 AM EST

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up…

Ian Cooper | Dec 23, 2025 at 8:58 AM EST

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the…

Rich Duprey | Nov 3, 2025 at 10:13 AM EST

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that…

Ian Cooper | Oct 31, 2025 at 10:18 AM EDT

3 Explosive Stocks With High Short Interest

Short interest is always a sign of how bearish investors may be on a stock. But it can also serve…

Ian Cooper | Oct 30, 2025 at 9:40 AM EDT

3 Explosive Stocks With High Short Interest

High short interest can help investors identify potential high risks. And, it can also be a sign of a possible…

Rich Duprey | Aug 27, 2025 at 8:23 AM EDT

Eli Lilly’s Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race

A Fierce Battle for Weight-Loss Supremacy The weight-loss drug market has become a battleground, ignited by the runaway success of…

Rich Duprey | Aug 22, 2025 at 12:13 PM EDT

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in…